Mentions of environmental sustainability increased in the pharmaceutical industry in Q1 2023
Notably, environmental sustainability was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of robotics and social, according to GlobalData.
Of the 50 leading companies in the pharmaceutical industry, Novozymes had the greatest increase in references for environmental sustainability in Q1 2023, compared with the previous quarter. GlobalData identified 349 environmental sustainability-related sentences in the company’s filings – 46% of all sentences – and an increase of 600% in Q1 2023 compared with Q4 2022. Bayer’s mentions of environmental sustainability rose by 3800% to 275 and GSK’s by 20000% to 201 and Novartis’s by 1500% to 165 and Pfizer’s by 1600% to 137.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for environmental sustainability in Q1 2023 was 107.
To further understand GlobalData’s analysis on ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.
Source link
#Mentions #environmental #sustainability #increased #pharmaceutical #industry
